Technical Analysis for ASRT - Assertio Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
ASRT closed down 0.47 percent on Thursday, January 17, 2019, on 23 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|Weak or Absent||Down||Down||Down|
|See historical ASRT trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||NR7||Range Contraction||0.00%|
|Jan 17||Inside Day||Range Contraction||0.00%|
|Jan 16||Outside Day||Range Expansion||-0.47%|
|Jan 15||NR7||Range Contraction||-1.18%|
|Jan 15||NR7-2||Range Contraction||-1.18%|
|Jan 14||NR7||Range Contraction||-0.47%|
|Jan 10||Overbought Stochastic||Strength||1.69%|
|Jan 9||Bearish Engulfing||Bearish||2.44%|
|Jan 9||New Downtrend||Bearish||2.44%|
|Jan 9||Stochastic Sell Signal||Bearish||2.44%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ASRT news...
|52 Week High||9.48|
|52 Week Low||3.37|
|200-Day Moving Average||6.2175|
|50-Day Moving Average||4.5468|
|20-Day Moving Average||3.9755|
|10-Day Moving Average||4.223|
|Average True Range||0.2579|
|Chandelier Exit (Long, 3 ATRs )||3.8163|
|Chandelier Exit (Short, 3 ATRs )||4.1437|
|Upper Bollinger Band||4.5332|
|Lower Bollinger Band||3.4178|
|Percent B (%b)||0.7|
|MACD Signal Line||-0.1266|
|Market Cap||264.55 Million|
|Num Shares||63 Million|
|Price-to-Earnings (P/E) Ratio||-2.35|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||4.40|
|Resistance 3 (R3)||4.39||4.33||4.36|
|Resistance 2 (R2)||4.33||4.28||4.33||4.35|
|Resistance 1 (R1)||4.26||4.25||4.23||4.27||4.34|
|Support 1 (S1)||4.13||4.15||4.10||4.14||4.06|
|Support 2 (S2)||4.07||4.12||4.07||4.05|
|Support 3 (S3)||4.00||4.07||4.04|
|Support 4 (S4)||4.01|